Patents by Inventor Linus Lin
Linus Lin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10515856Abstract: A method includes forming first and second fins of a finFET extending above a semiconductor substrate, with a shallow trench isolation (STI) region in between, and a distance between a top surface of the STI region and top surfaces of the first and second fins. First and second fin extensions are provided on top and side surfaces of the first and second fins above the top surface of the STI region. Material is removed from the STI region, to increase the distance between the top surface of the STI region and top surfaces of the first and second fins. A conformal stressor dielectric material is deposited over the fins and STI region. The conformal dielectric stressor material is reflowed, to flow into a space between the first and second fins above a top surface of the STI region, to apply stress to a channel of the finFET.Type: GrantFiled: February 8, 2019Date of Patent: December 24, 2019Assignee: Taiwan Semiconductor Manufacturing Co., Ltd.Inventors: Chia-Pin Linus Lin, Chien-Tai Chan, Hsien-Chin Lin, Shyue-Shyh Lin
-
Publication number: 20080076805Abstract: The acyclic hydrazides of the invention are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders (including smoking cessation), the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.Type: ApplicationFiled: October 3, 2005Publication date: March 27, 2008Inventors: Linus Lin, Ping Liu
-
Publication number: 20070179190Abstract: Compounds of Formula I are antagonists of VLA-4, and as such are useful in the inhibition or prevention of cell adhesion and cell-adhesion mediated pathologies. These compounds may be formulated into pharmaceutical compositions and are suitable for use in the treatment of inflammatory bowel disease including ulcerative colitis and Crohn's disease, multiple sclerosis, asthma, and rheumatoid arthritis.Type: ApplicationFiled: March 7, 2005Publication date: August 2, 2007Applicant: MERCK & CO., INC.Inventors: William Hagmann, Linus Lin, Ping Liu, Richard Mumford, Thomas Reger, Nicholas Smith, Nicholas Stock, Jasmine Zunic
-
Publication number: 20070105914Abstract: The substituted sulfonamides of the invention are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.Type: ApplicationFiled: September 14, 2004Publication date: May 10, 2007Inventors: Helen Armstrong, Linda Chang, Ravindra Guthikonda, William Hagmann, Linus Lin, Shrenik Shah
-
Publication number: 20060115425Abstract: The present invention relates to particular radiolabeled Cannabinoid-1 (CB1) receptor modulators, and methods of using these modulators for labeling and diagnostic imaging of Cannabinoid-1 receptors in mammals, particularly humans. In addition, intermediates useful for the synthesis of the radiolabeled Cannabinoid-1 receptor modulators are also disclosed, as well as the processes for synthesizing the radiolabeled Cannabinoid-1 receptor modulators. Still further, formulations of the radiolabeled Cannabinoid-1 receptor compounds are described.Type: ApplicationFiled: June 25, 2004Publication date: June 1, 2006Inventors: H. Donald Burns, Alex Chen, Raymond Gibson, Mark Goulet, William Hagmann, Terence Hamill, James Jewell, Linus Lin, Ping Liu, Andrey Peresypkin
-
Publication number: 20060106071Abstract: Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.Type: ApplicationFiled: December 15, 2003Publication date: May 18, 2006Inventors: Linus Lin, William Hagmann, Sanjeev Kumar, Wenji Yin, George Doss
-
Publication number: 20050239828Abstract: Novel compounds of structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as psychotropic drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinsons disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as, the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.Type: ApplicationFiled: March 21, 2003Publication date: October 27, 2005Applicant: Merck & Co., Inc.Inventors: William Hagmann, Linus Lin, Shrenik Shah, Mark Goulet, James Jewell
-
Publication number: 20050234061Abstract: Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.Type: ApplicationFiled: April 19, 2005Publication date: October 20, 2005Inventors: William Hagmann, Linus Lin, Shrenik Shah, Ravindra Guthikonda, Hongbo Qi, Linda Chang, Ping Liu, Helen Armstrong, James Jewell, Thomas Lanza
-
Publication number: 20050203112Abstract: Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.Type: ApplicationFiled: April 8, 2003Publication date: September 15, 2005Inventors: Laurie Castonguay, William Hagmann, Linus Lin, Shrenik Shah
-
Publication number: 20050154202Abstract: Novel compounds of structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as psychotropic drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as, the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.Type: ApplicationFiled: April 1, 2003Publication date: July 14, 2005Inventors: William Hagmann, Linus Lin, Shrenik Shah
-
Patent number: 6431351Abstract: A case for a pair of far-sighted eyeglasses includes an upper and a lower half case, a pair of far-sighted eyeglasses and a pen. The upper and the lower half case have a soft cloth, and the lower half case has a position block in an intermediate portion to stabilize the far-sighted eyeglasses with the nose bridge of the far-sighted eyeglasses lying on the position block. The lower half case has a shaped retaining block respectively at two opposite sides for keeping a pen stably. Thus the case contains both the pair of far-sighted eyeglasses and the pen for carrying to wear and write. A hang hook is also provided on an outer surface of the upper half case to be hanged on a pocket.Type: GrantFiled: January 23, 2001Date of Patent: August 13, 2002Inventor: Linus Lin
-
Publication number: 20020096439Abstract: A case for a pair of far-sighted eyeglasses includes an upper and a lower half case, a pair of far-sighted eyeglasses and a pen. The upper and the lower half case have a soft cloth, and the lower half case has a position block in an intermediate portion to stabilize the far-sighted eyeglasses with the nose bridge of the far-sighted eyeglasses lying on the position block. The lower half case has a shaped retainable block respectively at two opposite sides for keeping a pen stably. Thus the case contains both the pair of far-sighted eyeglasses and the pen for carrying to wear and write. A hang hook is also provided on an outer surface of the upper half case to be hanged on a pocket.Type: ApplicationFiled: January 23, 2001Publication date: July 25, 2002Inventor: Linus Lin
-
Patent number: 6053309Abstract: A pair of far-sighted eyeglasses with a case includes a case consisting of an upper half case and a lower half case, and a pair of far-sighted eyeglasses. The eyeglasses have two elastic temples with curved portions that protrude slightly beyond an upper edge of the lower half case when placed in the case such that the temples are compressed by the upper half case when the case is closed. When the upper half case is disengaged from the lower half case for opening, the upper half case is pushed away from the lower half case by the temples recovering the elasticity of the curved portions so as to facilitate the opening of the case, without the possibility of the eyeglasses falling out of the case during opening.Type: GrantFiled: February 8, 1999Date of Patent: April 25, 2000Inventor: Linus Lin
-
Patent number: D438001Type: GrantFiled: June 12, 2000Date of Patent: February 27, 2001Inventor: Linus Lin
-
Patent number: D438002Type: GrantFiled: July 27, 2000Date of Patent: February 27, 2001Inventor: Linus Lin
-
Patent number: D462837Type: GrantFiled: September 28, 2001Date of Patent: September 17, 2002Inventor: Linus Lin